CCL2 and idiopathic pulmonary fibrosis: Interestingly, although CCL2 serum concentrations were elevated in IPF patients, Raghu’s trial on the use of carlumab, a CCL inhibitor, in these patients did not show any notable impact on pulmonary function tests [53].